ClinicalTrials.gg
RecruitingNCT07503808Updated Nov 10, 2026

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

A Phase 1 interventional study of IDE034 in Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by IDEAYA Biosciences. Recruiting at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by IDEAYA Biosciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Nov 10, 2026First sites in Georgia and Spain11 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Esophageal Squamous Cell Carcinoma with a site in United States — 43 open to participants now, 51 under way, 3 of them phase 3. Esophageal Squamous Cell Carcinoma · United States.

Planned enrollment
41st of 121
150 · median 61
Started
2026
with 11 others
Phase 1
44 of 139
15 open now
Primary completion
2027-07
later than 18 of 50 live
Registered
132nd of 139
by date

Among the 139 studies in Esophageal Squamous Cell Carcinoma with a site in United States, this one is the 41st largest by planned enrollment of the 121 interventional ones that give a count, is one of 12 that started in 2026, is one of 44 in phase 1, reaches primary completion later than 18 of the 50 other live ones, and was the 132nd registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 270 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

43 of the 139 studies in Esophageal Squamous Cell Carcinoma with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 181 Esophageal Squamous Cell Carcinoma studies recruiting now, 84 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Esophageal Squamous Cell Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Read the detailed description

Part 1 - Dose escalation Part 1 will evaluate increasing doses of IDE034 to assess safety, tolerability, and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) in subjects with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

Part 2 - Dose Expansion Part 2 will evaluate participants with B7-H3 and PTK7 expressing advanced/metastatic solid tumors at 2 or more dose levels determined to be safe and tolerable during dose escalation. The goal of Part 2 is to identify which of the doses evaluated in Part 1 is safe, well tolerated and results in tumor responses.

In parallel a basket cohort may be enrolled at one of the expansion dose(s) for which the tumor types and other selection criteria will be based on emerging data from nonclinical and Part 1 clinical evaluations. Additional selection criteria may be applied to the expansion indications (e.g., histological subset or select molecular alterations) based on emerging data.

03

Conditions studied

  • Esophageal Squamous Cell Carcinoma
  • High Grade Serous Ovarian Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Colorectal Cancer
  • Castration-resistant Prostate Cancer
  • Non Small Cell Lung Cancer
  • Endometrium Cancer
  • Triple Negative Breast Cancer

Keywords

  • Esophageal Squamous Cell Carcinoma
  • ESCC
  • Endometrial Cancer
  • Head and Neck Squamous Cell Carcinoma
  • HNSCC
  • Triple-negative Breast Cancer
  • TNBC
  • Colorectal Cancer
  • CRC
  • Non-small Cell Lung Cancer
  • NSCLC
  • High-grade Serous Ovarian Cancer
  • HGSOC
  • Advanced, Metastic Solid Tumors
  • B7-H3 (CD276) and Protein Tyrosine Kinase 7 (PTK7)
  • IDE034
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be at least 18 years of age or the age of maturity per local regulations
  2. Participants with advanced recurrent or solid tumors expressing B7-H3 and PTK7 in the following indications: NSCLC, ESCC, endometrial cancer, HGSOC, HNSCC, TNBC (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [] negative), CRC, and CRPC who have radiologically progressed or recurred on at least one or is intolerant to additional effective standard therapies.
  3. sample for testing
  4. Have performance status (ECOG PS) of 0 or 1.
  5. Have adequate bone marrow and organ function.
  6. Able to comply with /barrier requirements

Exclusion criteria

Exclusion Criteria:

  1. Known symptomatic or
  2. Known primary CNS and any other malignancies within 2 years prior to the first dose.
  3. Have uncontrolled tumor-associated pain
  4. Have cardiac abnormalities and/or cerebrovascular disease (stroke) within 6 months before the first dose
  5. Active uncontrolled infection
  6. Have history of interstitial pneumonitis, current noninfectious pneumonitis requiring therapy; known or suspected interstitial pneumonitis as seen on screening imaging; other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose.
  7. Have history of severe infections within 4 weeks prior to the start of study treatment, including but not limited to bacteremia, severe pneumonia, or other serious infectious complications requiring hospitalization.
  8. Have history of immunodeficiency, with a positive (HIV) test at screening.
  9. Participants with known or suspected viral hepatitis
  10. Have history of active tuberculosis within 1 year before enrollment
  11. If participants had adverse reactions to previous antitumor treatment that have not recovered to guidelines of Grade ≤ 1 and Grade 2 peripheral neurological symptoms
  12. Have received chemotherapy within 3 weeks of first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 3 weeks before the first dose of IMP or other products within 4 weeks of first dose of IMP
  13. Administration of any of the following

    1. Current use or anticipated need for food or drugs that are known strong /5 inhibitors or inducers
    2. Have prior treatment with B7-H3 or PTK7 antibody-drug conjugate (ADC).
    3. Have prior treatment with a topoisomerase I inhibitor (TOP1i), including an ADC with a TOP1i payload, within 6 months of first dose of IMP
    4. Have received radiotherapy within 2 weeks prior to study entry
    5. Have undergone major surgery or trauma within 4 weeks prior to study entry.
    6. Have received within 28 days prior to the first dose or are expected to receive live attenuated vaccine during the study treatment.
    7. Female participants who are pregnant, lactating, or planning to become pregnant during the study period to 7 months after the last dose of IMP.
    8. Are known to be allergic to any component or of the IMP product or have a history of severe allergic reactions to other monoclonal antibody/fusion protein drugs.
    9. Participants with complications in the eye including ulcers in the eye, and severe dry eye
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Part 1:IDE034 Dose Escalation

    IDE034 Dose Escalation Successive cohorts of participants will be treated with increasing doses of IDE034 until the maximum tolerated dose or the recommended dose for expansion is determined

    Drug: IDE034

  • Experimental
    Part 2: IDE034 Dose Expansion

    IDE034 Dose Expansion To further assess the safety, tolerability, and preliminary antitumor activity at one or more dose levels of IDE034 selected from dose escalation

    Drug: IDE034

Interventions

  • DrugIDE034

    IDE034

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of IDE034 in Part 1 dose escalation

    Incidence of dose limiting toxicities; incidence and severity of AEs and SAEs graded based on CTCAE V6.0

    Time frame: 21 days following the first dose of IDE034

  2. Safety and tolerability of IDE034 in Part 2 dose expansion

    Incidence of dose limiting toxicities; incidence and severity of AEs and SAEs graded based on CTCAE V6.0

    Time frame: Approximately 20 months total study duration

  3. To evaluate preliminary anti-tumor activity of IDE034 in Part 2 dose expansion

    Objective Response Rate (ORR) per RECIST v1.1

    Time frame: Time Frame: Approximately 20 months total study duration

  4. To evaluate preliminary anti-tumor activity of IDE034 in Part 2 dose expansion

    Duration of Response (DoR) per RECIST v1.1

    Time frame: Time Frame: Approximately 20 months total study duration

Secondary outcomes

  1. To evaluate preliminary anti-tumor activity of IDE034 in Part 1 dose escalation

    Objective Response Rate (ORR) per RECIST v1.1

    Time frame: Approximately 20 months total study duration

  2. To evaluate preliminary anti-tumor activity of IDE034 in Part 1 dose escalation

    Duration of Response (DoR) per RECIST v1.1

    Time frame: Approximately 20 months total study duration

  3. To further characterize preliminary anti-tumor activity of IDE034 in Part 1 dose escalation

    Disease Control Rate (DCR) per RECIST v1.1

    Time frame: Approximately 20 months total study duration

  4. To further characterize preliminary anti-tumor activity of IDE034 in Part 1 dose escalation

    Duration of response per RECIST v1.1

    Time frame: Approximately 20 months total study duration

  5. To further characterize preliminary anti-tumor activity of IDE034 in Part 2 dose expansion

    Disease Control Rate (DCR) per RECIST v1.1

    Time frame: Approximately 20 months total study duration

  6. To further characterize preliminary anti-tumor activity of IDE034 in Part 2 dose expansion

    Duration of response per RECIST v1.1

    Time frame: Approximately 20 months total study duration

  7. Pharmacokinetics (PK) of IDE034 and its constituents:

    Area under concentration time curve from time 0 to the last quantifiable concentration (AUClast)

    Time frame: Approximately 20 months total study duration

  8. Pharmacokinetics (PK) of IDE034 and its constituents

    Area under concentration time curve from time 0 to the end of dosing interval (AUCtau)

    Time frame: Approximately 20 months total study duration

  9. Pharmacokinetics (PK) of IDE034 and its constituents

    Maximum observed concentration (Cmax)

    Time frame: Approximately 20 months total study duration

  10. Pharmacokinetics (PK) of IDE034 and its constituents

    time to maximum observed concentration (Tmax)

    Time frame: Approximately 20 months total study duration

  11. Pharmacokinetics (PK) of IDE034 and its constituents

    concentration observed immediately prior to the next dose (Ctrough)

    Time frame: Approximately 20 months total study duration

  12. To evaluate immunogenicity of IDE034

    Anti-IDE034 antibody incidence and titers will be determined

    Time frame: Approximately 20 months total study duration

07

Study locations

26 of 26 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jul 2027, 17 months after the start.

Of 42 phase 1 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 68. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 31, 2026
StartActual
Feb 24, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added — first sites in Georgia and Spain
Show 11 added (7 United States, 2 Georgia, 2 Spain)
  • City of Hope Comprehensive Cancer Center · Duarte, United States
  • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
  • Yale Cancer Center · New Haven, United States
  • AdventHealth Celebration · Celebration, United States
  • Florida Clinical Trials Group · Plantation, United States
  • START New Jersey · East Brunswick, United States
  • Columbia University Irving Medical Center · New York, United States
  • LTD High Technology Hospital Medcenter · Batumi, Georgia
  • Multiprofile Clinic Consilium Medulla · Tbilisi, Georgia
  • START Rioja - Hospital Universitario San Pedro · Logroño, Spain
  • START Madrid - Hospital Universitario HM Sanchinarro - CIOCC · Madrid, Spain
Nov 10, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Florida Cancer Specialists · Sarasota, United StatesContact s•••@partnersimage.com→k•••@flcancer.com
  • Karmanos Cancer Institute · Detroit, United StatesContact g•••@karmanos.org · •••6266→s•••@karmanos.org · •••6266
  • NEXT Texas LLC - San Antonio · San Antonio, United StatesContact d•••@nextoncology.com · •••9500→d•••@nextoncology.com · •••9500
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    11 sites added — first sites in Georgia and Spain
    Show 11 added (7 United States, 2 Georgia, 2 Spain)
    • City of Hope Comprehensive Cancer Center · Duarte, United States
    • City of Hope Orange County Lennar Foundation Cancer Center · Irvine, United States
    • Yale Cancer Center · New Haven, United States
    • AdventHealth Celebration · Celebration, United States
    • Florida Clinical Trials Group · Plantation, United States
    • START New Jersey · East Brunswick, United States
    • Columbia University Irving Medical Center · New York, United States
    • LTD High Technology Hospital Medcenter · Batumi, Georgia
    • Multiprofile Clinic Consilium Medulla · Tbilisi, Georgia
    • START Rioja - Hospital Universitario San Pedro · Logroño, Spain
    • START Madrid - Hospital Universitario HM Sanchinarro - CIOCC · Madrid, Spain
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Florida Cancer Specialists · Sarasota, United StatesContact s•••@partnersimage.com→k•••@flcancer.com
    • Karmanos Cancer Institute · Detroit, United StatesContact g•••@karmanos.org · •••6266→s•••@karmanos.org · •••6266
    • NEXT Texas LLC - San Antonio · San Antonio, United StatesContact d•••@nextoncology.com · •••9500→d•••@nextoncology.com · •••9500
    + 2 other changes: verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07503808
Lead sponsor
IDEAYA Biosciences
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Feb 24, 2026
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

IDEAYA Clinical Trials
Contact
IDEAYAClinicalTrials@ideayabio.com
1-855-433-2246

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion